EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study

Luis Ortega-Paz iD, Francesco Franchi, Fabiana Rollini, Mattia Galli iD, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M Pineda, Siva Suryadevara und 4 weitere

Thrombosis and Haemostasis · 01.03.2024 · 124 (03) · 263-273

DOI: 10.1055/a-2098-6639 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2024. Verfasst von Luis Ortega-Paz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To date, there are no data on switching to dual pathway inhibition (DPI) patients who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen.

Objectives

To assess the feasibility of switching from DAPT to DPI and to compare the pharmacodynamic (PD) profiles of these treatments.

Methods

This was a prospective, randomized, PD study conducted in 90 patients with chronic coronary syndrome (CCS) on DAPT with aspirin (81 mg/qd) plus a P2Y12 inhibitor (clopidogrel [75 mg/qd; n = 30], ticagrelor [90 mg/bid; n = 30], or prasugrel [10 mg/qd; n = 30]). Patients in each cohort were randomized to maintain DAPT or switch to DPI (aspirin 81 mg/qd plus rivaroxaban 2.5 mg/bid). PD assessments included: VerifyNow P2Y12 reaction units; light transmittance aggregometry following stimuli with adenosine diphosphate (ADP), tissue factor (TF), and a combination of collagen, ADP, and TF (maximum platelet aggregation %); thrombin generation (TG). Assays were performed at baseline and 30 days postrandomization.

Results

Switching from DAPT to DPI occurred without major side effects. DAPT was associated with enhanced P2Y12 inhibition, while DPI with reduced TG. Platelet-mediated global thrombogenicity (primary endpoint) showed no differences between DAPT and DPI in the ticagrelor (14.5% [0.0–63.0] vs. 20.0% [0.0–70.0]; p = 0.477) and prasugrel (20.0% [0.0–66.0] vs. 4.0% [0.0–70.0]; p = 0.482), but not clopidogrel (27.0% [0.0–68.0] vs. 53.0% [0.0–81.0]; p = 0.011), cohorts.

Conclusion

In patients with CCS, switching from different DAPT regimens to DPI was feasible, showing enhanced P2Y12 inhibition with DAPT and reduced TG with DPI, with no differences in platelet-mediated global thrombogenicity between DPI and ticagrelor- and prasugrel-, but not clopidogrel-, based DAPT. Clinical Trial Registration http://www.clinicaltrials.gov Unique Identifier: NCT04006288.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionHumansAspirinPlatelet Aggregation InhibitorsTicagrelorRivaroxabanPrasugrel HydrochlorideProspective StudiesAdenosineClopidogrelAdenosine DiphosphatePurinergic P2Y Receptor Antagonists

Substanzen

AspirinPlatelet Aggregation InhibitorsTicagrelorRivaroxabanPrasugrel HydrochlorideAdenosineClopidogrelAdenosine DiphosphatePurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
  • Departmet of Cardiology, Maria Cecilia Hospital, GVM Care and Research, Cotignola, Italy.
  • MLM Medical Labs, LLC, Memphis, Tennessee, United States.

ORCID-Profile: Luis Ortega-Paz, Mattia Galli, Dominick J Angiolillo

Förderung

  • Janssen Research and Development

Zitieren

APA

Ortega-Paz, L., Franchi, F., Rollini, F., Galli, M., Been, L., Ghanem, G., Shalhoub, A., Ossi, T., Rivas, A., Zhou, X., Pineda, A. M., Suryadevara, S., Soffer, D., Zenni, M. M., Jennings, L. K., & Angiolillo, D. J. (2024). Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Thrombosis and Haemostasis, 124(03), 263-273. https://doi.org/10.1055/a-2098-6639

Vancouver

Ortega-Paz L, Franchi F, Rollini F, Galli M, Been L, Ghanem G, et al. Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Thrombosis and Haemostasis. 2024;124(03):263-273. doi:10.1055/a-2098-6639

BibTeX
@article{OrtegaPaz2024,
  author = {Ortega-Paz, Luis and Franchi, Francesco and Rollini, Fabiana and Galli, Mattia and Been, Latonya and Ghanem, Ghussan and Shalhoub, Awss and Ossi, Tiffany and Rivas, Andrea and Zhou, Xuan and Pineda, Andres M and Suryadevara, Siva and Soffer, Daniel and Zenni, Martin M and Jennings, Lisa K and Angiolillo, Dominick J},
  title = {Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {03},
  pages = {263--273},
  doi = {10.1055/a-2098-6639}
}
Kostenlos starten →